TABLE 3.
Univariate Analysis of Relationship Between Patient Level Outcome Measures and Covariates
| Outcome |
||||||
|---|---|---|---|---|---|---|
| OR |
CR |
PFS |
||||
| Parameter | Odds ratio* | P | Odds ratio* | P | HR* | P |
| Sex (M vs. F) | 0.607 | 0.526 | 0.813 | 0.777 | 1.311 | 0.532 |
| Age (y) | 0.998 | 0.431 | 0.973 | 0.327 | 1.015 | 0.348 |
| Stage (III/IV vs. I/II) | 2.333 | 0.211 | 1.571 | 0.493 | 0.775 | 0.513 |
| Histology (transformed vs. indolent) | 0.550 | 0.455 | 0.640 | 0.584 | 1.492 | 0.362 |
| Presence of bulky disease (Y vs. N) | 0.163 | 0.024 | 0.400 | 0.242 | 1.604 | 0.291 |
| Number of tumor sites | 1.365 | 0.122 | 1.199 | 0.305 | 0.976 | 0.808 |
| Marrow involvement (Y vs. N) | 4.285 | 0.094 | 1.909 | 0.361 | 1.131 | 0.762 |
| Elevated lactate dehydrogenase (Y vs. N) | 0.824 | 0.784 | 1.250 | 0.748 | 1.488 | 0.313 |
| Chemotherapy refractory (Y vs. N) | 0.500 | 0.310 | 0.400 | 0.167 | 1.401 | 0.397 |
| No. of prior chemotherapies | 0.612 | 0.137 | 0.569 | 0.131 | 1.257 | 0.193 |
| Tracer-predicted tumor-absorbed dose (cGy)† | 1.468 | 0.061 | 1.535 | 0.032 | 0.773 | 0.020 |
| Therapy-delivered tumor-absorbed dose (cGy)† | 1.455 | 0.060 | 1.331 | 0.100 | 0.750 | 0.025 |
| Therapy-delivered tumor equivalent biologic effect† | 1.557 | 0.011 | 1.306 | 0.022 | 0.894 | 0.035 |
*
Odds ratio and HR calculated for 50-cGy change in absorbed dose, 0.15-unit change in equivalent biologic effect, and 1-unit change in other continuous factors.
†
Averaged over multiple tumors in each patient.